Last reviewed · How we verify
NCT05703516
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
trial testing Capmatinib in Non-Small-Cell Lung Carcinoma in 250 participants. Currently enrolling.
31 October 2026
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 12 June 2023 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 October 2026 |
| Sites | 12 locations across South Korea |
Drugs / interventions tested
- Capmatinib (CAPMATINIB) — full drug profile →
Conditions studied
- Non-Small-Cell Lung Carcinoma — all drugs for Non-Small-Cell Lung Carcinoma →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
Adults 18 to 100, any sex, with Non-Small-Cell Lung Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open label, prospective, multicenter, non-comparative study to assess the safety and effectiveness of Tabrecta® (Capmatinib) in real world setting. Also, this study is to fulfill the regulatory requirements as part of the RMP (Risk Management Plan) for Tabrecta® (Capmatinib), as requested by Korea Health Authority, MFDS (Ministry of Food and Drug Safety).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05703516
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Capmatinib
Trials testing the same drug.
- NCT06054191 — Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations · Phase 2 · not yet recruiting
- NCT05642572 — Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A L · Phase 2 · recruiting
- NCT05488314 — A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer · Phase 1, PHASE2 · active not recruiting
- NCT05243641 — Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients W · Phase 1, PHASE2 · terminated
- NCT05435846 — Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation · Phase 1 · terminated
Other recruiting trials for Non-Small-Cell Lung Carcinoma
Currently open trials in the same condition.
- NCT05708599 — A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer · NA · active not recruiting
- NCT05037825 — The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors · recruiting
- NCT04995523 — A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC · Phase 1, PHASE2 · active not recruiting
- NCT02905591 — A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC · Phase 2 · active not recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05703516 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 14 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05703516.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing